124 related articles for article (PubMed ID: 38461815)
1. The effect of mind-body intervention on lymphocyte doubling time and treatment free survival in treatment-naïve chronic lymphocytic leukemia patients.
Shapira S; Hirschberger N; Ofran Y; Mizrahi B; Mandel E; Benjamini O; Rabinowicz N; Zoref-Lorenz A
Acta Haematol; 2024 Mar; ():. PubMed ID: 38461815
[TBL] [Abstract][Full Text] [Related]
2. Global histone deacetylase enzymatic activity is an independent prognostic marker associated with a shorter overall survival in chronic lymphocytic leukemia patients.
Van Damme M; Crompot E; Meuleman N; Mineur P; Dessars B; El Housni H; Bron D; Lagneaux L; Stamatopoulos B
Epigenetics; 2014 Oct; 9(10):1374-81. PubMed ID: 25437053
[TBL] [Abstract][Full Text] [Related]
3. Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia.
Morabito F; Tripepi G; Moia R; Recchia AG; Boggione P; Mauro FR; Bossio S; D'Arrigo G; Martino EA; Vigna E; Storino F; Fronza G; Di Raimondo F; Rossi D; Condoluci A; Colombo M; Fais F; Fabris S; Foa R; Cutrona G; Gentile M; Montserrat E; Gaidano G; Ferrarini M; Neri A
Front Oncol; 2021; 11():684621. PubMed ID: 34408978
[TBL] [Abstract][Full Text] [Related]
4. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.
Herling CD; Cymbalista F; Groß-Ophoff-Müller C; Bahlo J; Robrecht S; Langerbeins P; Fink AM; Al-Sawaf O; Busch R; Porcher R; Cazin B; Dreyfus B; Ibach S; Leprêtre S; Fischer K; Kaiser F; Eichhorst B; Wentner CM; Hoechstetter MA; Döhner H; Leblond V; Kneba M; Letestu R; Böttcher S; Stilgenbauer S; Hallek M; Levy V
Leukemia; 2020 Aug; 34(8):2038-2050. PubMed ID: 32071431
[TBL] [Abstract][Full Text] [Related]
5. Leucocyte doubling time is a useful predictor of progression-free survival in chronic lymphocytic leukaemia.
Axdorph U; Nilsson BI; Nilsson BR; Björkholm M
J Intern Med; 1995 Feb; 237(2):205-9. PubMed ID: 7852924
[TBL] [Abstract][Full Text] [Related]
6. Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients.
Baumann T; Moia R; Gaidano G; Delgado J; Condoluci A; Villamor N; Payedimarri AB; Costa D; Patriarca A; Jiménez-Vicente C; Rossi D; Montserrat E
Leukemia; 2021 Aug; 35(8):2325-2331. PubMed ID: 33542480
[TBL] [Abstract][Full Text] [Related]
7. Frequency of TP53 Mutation in B-Cell Chronic Lymphocytic Leukaemia and its Association with Lymphocyte Doubling Time.
Ali SM; Irfan SM; Raza N
J Coll Physicians Surg Pak; 2023 Nov; 33(11):1249-1253. PubMed ID: 37926876
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia.
Molica S; Alberti A
Cancer; 1987 Dec; 60(11):2712-6. PubMed ID: 3677006
[TBL] [Abstract][Full Text] [Related]
9. Supplement of Vitamin D for early-stage Chronic Lymphocytic Leukemia Patients is Associated with a Longer Time to first Treatment.
Tadmor T; Melamed G; Alapi H; Gazit S; Patalon T; Rokach L
Blood Adv; 2024 May; ():. PubMed ID: 38701347
[TBL] [Abstract][Full Text] [Related]
10. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a 'Watch and Wait' Approach for Chemotherapy in Patients with Newly Diagnosed Advanced Non-small Cell Lung Cancer from a Diverse Community Population.
Noonan K; Tong KM; Laskin J; Zheng YY; Melosky B; Sun S; Murray N; Ho C
Clin Oncol (R Coll Radiol); 2015 Sep; 27(9):505-13. PubMed ID: 26095646
[TBL] [Abstract][Full Text] [Related]
12. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Chanan-Khan AA; Zaritskey A; Egyed M; Vokurka S; Semochkin S; Schuh A; Kassis J; Simpson D; Zhang J; Purse B; Foà R
Lancet Haematol; 2017 Nov; 4(11):e534-e543. PubMed ID: 28958469
[TBL] [Abstract][Full Text] [Related]
14. Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
Sorensen S; Wildgust M; Sengupta N; Trambitas C; Diels J; van Sanden S; Xu Y; Dorman E
Clin Ther; 2017 Jan; 39(1):178-189.e5. PubMed ID: 28062113
[TBL] [Abstract][Full Text] [Related]
15. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Sharman JP; Egyed M; Jurczak W; Skarbnik A; Pagel JM; Flinn IW; Kamdar M; Munir T; Walewska R; Corbett G; Fogliatto LM; Herishanu Y; Banerji V; Coutre S; Follows G; Walker P; Karlsson K; Ghia P; Janssens A; Cymbalista F; Woyach JA; Salles G; Wierda WG; Izumi R; Munugalavadla V; Patel P; Wang MH; Wong S; Byrd JC
Lancet; 2020 Apr; 395(10232):1278-1291. PubMed ID: 32305093
[TBL] [Abstract][Full Text] [Related]
16. Sex-dependent association of circulating sex steroids and pituitary hormones with treatment-free survival in chronic lymphocytic leukemia patients.
Allain EP; Venzl K; Caron P; Turcotte V; Simonyan D; Gruber M; Le T; Lévesque E; Guillemette C; Vanura K
Ann Hematol; 2018 Sep; 97(9):1649-1661. PubMed ID: 29781039
[TBL] [Abstract][Full Text] [Related]
17. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Langerbeins P; Zhang C; Robrecht S; Cramer P; Fürstenau M; Al-Sawaf O; von Tresckow J; Fink AM; Kreuzer KA; Vehling-Kaiser U; Tausch E; Müller L; Eckart MJ; Schlag R; Freier W; Gaska T; Balser C; Reiser M; Stauch M; Wendtner CM; Fischer K; Stilgenbauer S; Eichhorst B; Hallek M
Blood; 2022 Jan; 139(2):177-187. PubMed ID: 34758069
[TBL] [Abstract][Full Text] [Related]
18. Prognostic importance of soluble CD23 in B-cell chronic lymphocytic leukemia.
Saka B; Aktan M; Sami U; Oner D; Sanem O; Dinçol G
Clin Lab Haematol; 2006 Feb; 28(1):30-5. PubMed ID: 16430457
[TBL] [Abstract][Full Text] [Related]
19. A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia.
Lee CH; Chen PH; Lin C; Wang CY; Ho CL
PLoS One; 2020; 15(1):e0226879. PubMed ID: 31995577
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials.
Wojdacz TK; Amarasinghe HE; Kadalayil L; Beattie A; Forster J; Blakemore SJ; Parker H; Bryant D; Larrayoz M; Clifford R; Robbe P; Davis ZA; Else M; Howard DR; Stamatopoulos B; Steele AJ; Rosenquist R; Collins A; Pettitt AR; Hillmen P; Plass C; Schuh A; Catovsky D; Oscier DG; Rose-Zerilli MJJ; Oakes CC; Strefford JC
Blood Adv; 2019 Aug; 3(16):2474-2481. PubMed ID: 31434681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
